semaglutide fda changes The FDA's Latest on for Weight Loss fda compounding semaglutide news Important

Compounding rules tightened in 2026 Both drugs are off the FDA shortage list, so large-scale compounding is no longer broadly allowed it's now mostly limited to patients with a documented medical need, like an ingredient allergy or a non-standard dose

Because these products are classified as cosmetics rather than medicines, they are not subject to the same regulatory scrutiny as licensed pharmaceutical treatments

When we eat, the intestines release GLP-1, which has several functions in the body

Many patients observe changes occurring in a few weeks

For people with complex medical needs such as type 2 diabetes, kidney disease, gastrointestinal conditions or a history of bariatric surgery working with an APD is even more important

AAPS Journal